Isis cholesterol drug lowers LDL levels
26th March 2007, By Victoria Harrison
Isis Pharmaceuticals has said new results from its monotherapy phase II clinical trial of cholesterol drug showed improvements in LDL cholesterol.
Patients with high cholesterol were treated for ten weeks with 400 mg/week of the drug ISIS 301012. In this study, increasing the dose of ISIS 301012 to 400 mg/week was well tolerated and further reduced atherogenic lipids, with median improvements in LDL-cholesterol of 70%.
Read the full report here @ Pharmaceutical Business Review Online
No comments:
Post a Comment